Atezolizumab vs Enasidenib Mesylate

## Atezolizumab vs Enasidenib Mesylate: Overview

This comparison examines the pharmacological differences between **Atezolizumab** and **Enasidenib Mesylate**.

## Mechanism of Action

**Atezolizumab**: Fully human anti-PD-L1 IgG1 monoclonal antibody blocking PD-L1 interaction with PD-1 and B7.1.

## Pharmacokinetics

**Half-life**: Atezolizumab — 27 days; Enasidenib Mesylate — N/A.

## Chemical Properties

**Type**: Atezolizumab — Antibody; Enasidenib Mesylate — Small molecule.